Xiaolin Wang - Mar 1, 2022 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Role
EVP, Clinical Development
Signature
/s/ Jack Anders, as Attorney-in-fact for Xiaolin Wang
Stock symbol
RVMD
Transactions as of
Mar 1, 2022
Transactions value $
$0
Form type
4
Date filed
3/3/2022, 03:25 PM
Previous filing
Dec 21, 2021
Next filing
Mar 21, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Award $0 +20K +167.53% $0.00 31.9K Mar 1, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVMD Stock Option (Right to Buy) Award $0 +70K $0.00 70K Mar 1, 2022 Common Stock 70K $18.56 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 29,100 Restricted Stock Units.
F2 One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2022 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Remarks:

EVP, Clinical Development